232 related articles for article (PubMed ID: 23260229)
1. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function.
Hodge JM; Wang Y; Berk M; Collier FM; Fernandes TJ; Constable MJ; Pasco JA; Dodd S; Nicholson GC; Kennedy RL; Williams LJ
Biol Psychiatry; 2013 Jul; 74(1):32-9. PubMed ID: 23260229
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats.
Oosting RS; Chan JS; Olivier B; Banerjee P; Choi YK; Tarazi F
Psychopharmacology (Berl); 2016 Mar; 233(6):1025-34. PubMed ID: 26758283
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
4. Serotonin and fluoxetine modulate bone cell function in vitro.
Gustafsson BI; Thommesen L; Stunes AK; Tommeras K; Westbroek I; Waldum HL; Slørdahl K; Tamburstuen MV; Reseland JE; Syversen U
J Cell Biochem; 2006 May; 98(1):139-51. PubMed ID: 16408289
[TBL] [Abstract][Full Text] [Related]
5. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
6. Selective serotonin reuptake inhibitors (SSRI) affect murine bone lineage cells.
Durham E; Zhang Y; LaRue A; Bradshaw A; Cray J
Life Sci; 2020 Aug; 255():117827. PubMed ID: 32450170
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
Sánchez C; Hyttel J
Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
[TBL] [Abstract][Full Text] [Related]
8. Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective 5-HT reuptake inhibitors on 5-HT release.
Nagayasu K; Yatani Y; Kitaichi M; Kitagawa Y; Shirakawa H; Nakagawa T; Kaneko S
Br J Pharmacol; 2010 Dec; 161(7):1527-41. PubMed ID: 20698856
[TBL] [Abstract][Full Text] [Related]
9. [Selective serotonin reuptake inhibitor(SSRI)].
Motohashi N
Nihon Rinsho; 2001 Aug; 59(8):1519-22. PubMed ID: 11519151
[TBL] [Abstract][Full Text] [Related]
10. The pharmacogenetics of the selective serotonin reuptake inhibitors.
Brøsen K
Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
[TBL] [Abstract][Full Text] [Related]
11. Citalopram and sertraline exposure compromises embryonic bone development.
Fraher D; Hodge JM; Collier FM; McMillan JS; Kennedy RL; Ellis M; Nicholson GC; Walder K; Dodd S; Berk M; Pasco JA; Williams LJ; Gibert Y
Mol Psychiatry; 2016 May; 21(5):656-64. PubMed ID: 26347317
[TBL] [Abstract][Full Text] [Related]
12. Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect.
Ortuño MJ; Robinson ST; Subramanyam P; Paone R; Huang YY; Guo XE; Colecraft HM; Mann JJ; Ducy P
Nat Med; 2016 Oct; 22(10):1170-1179. PubMed ID: 27595322
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths.
Cao TXD; Filliter C; Montastruc F; Yu OHY; Fergusson E; Rej S; Azoulay L; Renoux C
J Affect Disord; 2022 Dec; 318():231-237. PubMed ID: 36084758
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).
Hyttel J
Int Clin Psychopharmacol; 1994 Mar; 9 Suppl 1():19-26. PubMed ID: 8021435
[TBL] [Abstract][Full Text] [Related]
15. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
16. The adverse skeletal effects of selective serotonin reuptake inhibitors.
Tsapakis EM; Gamie Z; Tran GT; Adshead S; Lampard A; Mantalaris A; Tsiridis E
Eur Psychiatry; 2012 Apr; 27(3):156-69. PubMed ID: 21295451
[TBL] [Abstract][Full Text] [Related]
17. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
Meyer JH; Wilson AA; Sagrati S; Hussey D; Carella A; Potter WZ; Ginovart N; Spencer EP; Cheok A; Houle S
Am J Psychiatry; 2004 May; 161(5):826-35. PubMed ID: 15121647
[TBL] [Abstract][Full Text] [Related]
18. Selective serotonin reuptake inhibitor exposure alters osteoblast gene expression and craniofacial development in mice.
Cray JJ; Weinberg SM; Parsons TE; Howie RN; Elsalanty M; Yu JC
Birth Defects Res A Clin Mol Teratol; 2014 Dec; 100(12):912-23. PubMed ID: 25308507
[TBL] [Abstract][Full Text] [Related]
19. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
[TBL] [Abstract][Full Text] [Related]
20. Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology.
Goodnick PJ; Goldstein BJ
J Psychopharmacol; 1998; 12(3 Suppl B):S5-20. PubMed ID: 9808077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
